Pressure BioSciences, Inc. Selected to Present at Cavendish Global Health Impact Forum

SOUTH EASTON, Mass., May 5, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced that it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY.  The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.  To accomplish this mission, the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis, and treatment.

Mr. Michael Moffat, Cavendish co-founder and President explains, "With the help of our expert advisors, we conducted a global search of research institutions and private-sector companies to identify organizations that meet the required standard of excellence.  The quality and originality of Pressure BioSciences' broadly enabling pressure cycling technology (PCT) platform positions them to make major contributions in supporting thousands of researchers around the world in their efforts to identify, control, prevent, and cure a host of diseases and disorders afflicting humans, animals, and plants."

"We are honored to be selected to present at this unique event, as we believe it is further recognition of the importance of our powerful and innovative PCT platform," said Mr. Richard T. Schumacher, President and CEO of PBI.  "Over 100 publications now cite the advantages of the PCT System in the development of improved testing methods to enhance the health and well-being of people worldwide.  These methods are used in areas such as (i) human disease and disorders, (ii) forensics, (iii) food safety, and (iv) agriculture.  We welcome the opportunity to interact with many of world's leading scientific minds, thought-leaders, and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people worldwide."

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making, and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.  Cavendish Global, together with the Global Partnerships Forum and the New York Academy of Sciences, organizes the Forum annually in New York.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.      

Further information is available on the Company's website: http://www.pressurebiosciences.com

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (taking place in New York at the United Nations Headquarters May 5th to 7th 2014), Europe (London, October 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

For more information: http://cavendishglobal.com

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Investor Contacts:

Richard T. Schumacher, President and CEO                           (508) 230-1828 (T)
Richard P. Thomley, CFO                                                      (508) 230-1829 (F)
Howard Gostfrand, President, American Capital Ventures         (305) 918-7000 (T)

SOURCE Pressure BioSciences, Inc.

RELATED LINKS
http://www.pressurebiosciences.com

reade more... Résuméabuiyad

Bruin Biometrics announces SEM Scanner™ and the 'sixth vital sign' to assess pressure ulcers

BBI Logo. (PRNewsFoto/Bruin Biometrics, LLC)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SOUTHAMPTON, England, March 27, 2014 /PRNewswire/ -- 2nd EPUAP Focus Meeting on Skin Health and the Microclimate, University of Southampton -- Bruin Biometrics, LLC ("BBI"), a biometric sensing medical device company today announced significant clinical breakthroughs in the assessment of pressure ulcers using BBI's SEM Scanner™, a CE marked medical device.

Bruin Biometrics will present these data in detail during a two-week EU clinical and policy presentation series under the theme, "Making Pressure Ulcer Prevention Possible," between March 31 and April 11, 2014, including a presentation at the 2nd Focus Meeting of the EPUAP April 7 – 9, 2014.

"We are living through a healthcare transformation that holds the promise of sparing millions of patients from unnecessary pain and potential early mortality. Policy makers across Europe, many of whom consider pressure ulcers to be unacceptable quality events, have crafted and are implementing policies that are increasingly holding healthcare providers financially responsible for the billions of Euro required to treat pressure ulcers," said Martin Burns, CEO of Bruin Biometrics. "The SEM ScannerTM is coming to market, with breakthrough clinical data, at a critical time for healthcare systems and aging populations."   

Interim results from BBI's clinical studies show statistically significant SEM ScannerTM readings from patients with confirmed Stage I ulcers, as well as Deep Tissue Injury (DTI). Three clinical breakthroughs have thus far been observed:

SEM readings at the center of a sacral pressure ulcers, where compromised tissue is present, are significantly lower than readings at the periphery of the pressure ulcer;   Around the periphery of the pressure ulcers, SEM readings converge toward those observed over vascularized, viable tissue as indicated by control site readings obtained from subjects' sternums; and, SEM readings at the center of existing sacral pressure ulcers are statistically different from SEM readings at the sacra in a population at risk for pressure ulcers and in healthy subjects.These data patterns have been independently observed in subjects across two separate study sites under the auspices of two autonomous principal investigators.

"These data hold tremendous clinical and economic value for practitioners assessing patients at admission, at discharge and during stay for the existence of pressure ulcers and deep tissue injuries," Burns said.

The current standard of care in pressure ulcer prevention is based on visual assessment, which focuses on areas where pressure ulcers most commonly develop: sacra and heels, for example. Unfortunately, the quality of visual skin inspection is highly dependent on the skill of the caregiver, and wide and varying results occur. By the time pressure-induced tissue damage is visually evident at the skin's surface, significant damage has already occurred.

The SEM Scanner can be used by all healthcare practitioners. And SEM Scanner readings – the 6th vital sign – are readily interpreted and tracked. The device uses integrated sensor technology to assess inflammatory changes associated with pressure-induced tissue damage.

"Pressure ulcers can be aggressively addressed as a problem if healthcare workers use the SEM ScannerTM as a part of their vital signs checks," Burns said. "Pressure ulcer scanning should be the sixth vital sign check of all at risk patients."

About Bruin Biometrics

Bruin Biometrics (BBI) is relentlessly committed to using technology to improve the way that health care is delivered. By developing innovative biometric medical device systems that can cost-effectively detect and monitor select medical conditions with urgent clinical need, BBI is helping inform clinical decisions, simplify patient care, and improve patient outcomes. BBI has developed the SEM ScannerTM, a revolutionary wound information medical device to detect the inflammatory changes associated with pressure induced tissue damage. BBI's second product, the OrthoSonosTM is an innovative medical device to detect and monitor the health of native joints and prosthetic implants. Neither SEM ScannerTM nor OrthoSonosTM are currently approved by the FDA for sale in the United States. The SEM ScannerTM has been CE Marked and is currently in full commercial launch in geographies recognizing CE Marking. OrthoSonosTM is on track for commercial launch in early 2015. To learn more about BBI please visit www.bruinbiometrics.com. 

Logo - http://photos.prnewswire.com/prnh/20131018/LA00429LOGO

SOURCE Bruin Biometrics, LLC

RELATED LINKS
http://www.bruinbiometrics.com

reade more... Résuméabuiyad

Bruin Biometrics announces SEM Scanner™ and the 'sixth vital sign' to assess pressure ulcers

BBI Logo. (PRNewsFoto/Bruin Biometrics, LLC)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SOUTHAMPTON, England, March 27, 2014 /PRNewswire/ -- 2nd EPUAP Focus Meeting on Skin Health and the Microclimate, University of Southampton -- Bruin Biometrics, LLC ("BBI"), a biometric sensing medical device company today announced significant clinical breakthroughs in the assessment of pressure ulcers using BBI's SEM Scanner™, a CE marked medical device.

Bruin Biometrics will present these data in detail during a two-week EU clinical and policy presentation series under the theme, "Making Pressure Ulcer Prevention Possible," between March 31 and April 11, 2014, including a presentation at the 2nd Focus Meeting of the EPUAP April 7 – 9, 2014.

"We are living through a healthcare transformation that holds the promise of sparing millions of patients from unnecessary pain and potential early mortality. Policy makers across Europe, many of whom consider pressure ulcers to be unacceptable quality events, have crafted and are implementing policies that are increasingly holding healthcare providers financially responsible for the billions of Euro required to treat pressure ulcers," said Martin Burns, CEO of Bruin Biometrics. "The SEM ScannerTM is coming to market, with breakthrough clinical data, at a critical time for healthcare systems and aging populations."   

Interim results from BBI's clinical studies show statistically significant SEM ScannerTM readings from patients with confirmed Stage I ulcers, as well as Deep Tissue Injury (DTI). Three clinical breakthroughs have thus far been observed:

SEM readings at the center of a sacral pressure ulcers, where compromised tissue is present, are significantly lower than readings at the periphery of the pressure ulcer;   Around the periphery of the pressure ulcers, SEM readings converge toward those observed over vascularized, viable tissue as indicated by control site readings obtained from subjects' sternums; and, SEM readings at the center of existing sacral pressure ulcers are statistically different from SEM readings at the sacra in a population at risk for pressure ulcers and in healthy subjects.These data patterns have been independently observed in subjects across two separate study sites under the auspices of two autonomous principal investigators.

"These data hold tremendous clinical and economic value for practitioners assessing patients at admission, at discharge and during stay for the existence of pressure ulcers and deep tissue injuries," Burns said.

The current standard of care in pressure ulcer prevention is based on visual assessment, which focuses on areas where pressure ulcers most commonly develop: sacra and heels, for example. Unfortunately, the quality of visual skin inspection is highly dependent on the skill of the caregiver, and wide and varying results occur. By the time pressure-induced tissue damage is visually evident at the skin's surface, significant damage has already occurred.

The SEM Scanner can be used by all healthcare practitioners. And SEM Scanner readings – the 6th vital sign – are readily interpreted and tracked. The device uses integrated sensor technology to assess inflammatory changes associated with pressure-induced tissue damage.

"Pressure ulcers can be aggressively addressed as a problem if healthcare workers use the SEM ScannerTM as a part of their vital signs checks," Burns said. "Pressure ulcer scanning should be the sixth vital sign check of all at risk patients."

About Bruin Biometrics

Bruin Biometrics (BBI) is relentlessly committed to using technology to improve the way that health care is delivered. By developing innovative biometric medical device systems that can cost-effectively detect and monitor select medical conditions with urgent clinical need, BBI is helping inform clinical decisions, simplify patient care, and improve patient outcomes. BBI has developed the SEM ScannerTM, a revolutionary wound information medical device to detect the inflammatory changes associated with pressure induced tissue damage. BBI's second product, the OrthoSonosTM is an innovative medical device to detect and monitor the health of native joints and prosthetic implants. Neither SEM ScannerTM nor OrthoSonosTM are currently approved by the FDA for sale in the United States. The SEM ScannerTM has been CE Marked and is currently in full commercial launch in geographies recognizing CE Marking. OrthoSonosTM is on track for commercial launch in early 2015. To learn more about BBI please visit www.bruinbiometrics.com. 

Logo - http://photos.prnewswire.com/prnh/20131018/LA00429LOGO

SOURCE Bruin Biometrics, LLC

RELATED LINKS
http://www.bruinbiometrics.com

reade more... Résuméabuiyad

Concise Analysis of the International Blood Pressure Monitoring Testing Market - Forecasts to 2019

DUBLIN, Feb. 24, 2014
/PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/j8sfj8/blood_pressure

) has announced the addition of the

"Concise Analysis of the International Blood Pressure Monitoring Testing Market - Forecasts to 2019"

report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The rise in prevalence of high/low blood pressure is attributed to a geriatric population, sedentary lifestyle, lack of physical activity and rising stress. It is estimated that people above the age of 55 years have 90% risk of developing high blood pressure. The global blood pressure monitoring testing market was valued at USD 1,713.3 million in 2012 and is expected to grow at a CAGR of 11.5% from 2013 to 2019, to reach an estimated value of USD 3,661.3 million by 2019. Social, behavioral and metabolic factors determine and contribute to hypertension. Behavioral risk factors such as physical inactivity, unhealthy diet, consumption of alcohol and tobacco, increase the risk of hypertension.

Manufacturers are coming up with new and innovative digital blood pressure monitoring devices that are easy to use and provide accurate readings instantly. The digital sphygmomanometers market is expected to grow at a faster rate compared to other types of sphygmomanometers (mercury and aneroid) as they are easy to use and provide accurate results. The trend of regular monitoring is fast catching up, with patients opting for automated self-care, thus making use of personal monitoring devices. Currently, majority of the automated blood pressure monitoring devices available are based on the oscillometric method that gives accurate results, along with ease of use.

Key Topics Covered:

1 Preface

2 Executive Summary

3 Market Overview

4 Blood Pressure Monitoring Testing Market, By Segments

5 Blood Pressure Monitoring Testing Market, By Geography

6 Blood Pressure Monitoring Testing Market, By End Users

7 Competitive Landscape

8 Recommendations

9 Company Profiles

Companies Mentioned:

A&D Medical, Inc CONTEC MEDICAL SYSTEMS CO, LTD Covidien PLC GE Healthcare Masimo Corporation Nihon Kohden Corporation Omron Healthcare, Inc Philips Healthcare Shenzhen Mindray Bio-Medical Electronics Co, Ltd Spacelabs Healthcare Suntech Medical, Inc Welch Allyn For more information visit http://www.researchandmarkets.com/research/j8sfj8/blood_pressure

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets

RELATED LINKS
http://www.researchandmarkets.com

reade more... Résuméabuiyad

Bruin Biometrics, LLC Awarded CE Mark for the SEM Scanner, an Innovative Diagnostic Tool to Detect Pressure Induced Tissue Damage

BBI Logo. (PRNewsFoto/Bruin Biometrics, LLC)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";LOS ANGELES, Nov. 13, 2013 /PRNewswire/ -- Bruin Biometrics, LLC ("BBI") announced today that it has received CE Marking (Conformite Europeenne) in the European Union to market the SEM Scanner. The SEM Scanner is a Class IIA medical device that is intended to detect localized tissue edema and pressure induced tissue damage that may lead to the formation of pressure ulcers (also known as pressure sores, or decubitus ulcers) before damage becomes visible on the skin's surface.

(Logo: http://photos.prnewswire.com/prnh/20131018/LA00429LOGO)

The hand-held, portable SEM Scanner is a point of care diagnostic tool that measures increased fluid content within the skin and underlying tissue known as subepidermal moisture (SEM). SEM can serve as a biophysical marker of inflammation indicative of impending skin damage and pressure ulcer formation. In clinical studies, SEM has been shown to identify pressure-induced tissue damage — including pressure ulcers — up to 10 days before damage becomes visible on the skin's surface.

Early detection of pressure ulcers with the SEM Scanner can lead to targeted interventions, reduced ulceration severity, and early recovery, as well as decreased hospital days. Additional advantages of the SEM Scanner over other diagnostic modalities include objective, evidence-based measurements; non-invasive, rapid results; clear risk assessment documentation; standardized patient assessment; and minimal technical skills for operation.

BBI developed the SEM Scanner in conjunction with research colleagues at the University of California at Los Angeles (UCLA), notably Barbara Bates-Jensen, PhD, RN, CWOCN, FAAN. Bates-Jensen serves as Chair of the Faculty Executive Committee at the UCLA School of Nursing and Associate Adjunct Professor, Medicine at the UCLA David Geffen School of Medicine.

BBI will officially launch the SEM Scanner at the upcoming MEDICA conference taking place in Dusseldorf, Germany, November 20-23, 2013. For additional information, please visit www.bruinbiometrics.com.

SOURCE Bruin Biometrics, LLC

RELATED LINKS
http://www.bruinbiometrics.com

reade more... Résuméabuiyad